MoonLake Immunotherapeutics (MLTX) Change in Account Payables (2021 - 2026)

MoonLake Immunotherapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$6.2 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 304.88% year-over-year to -$6.2 million in Q1 2026; TTM through Mar 2026 was $11.4 million, a 33.45% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 187.35% from the prior year.
• Change in Account Payables fell to -$6.2 million in Q1 2026 per MLTX's latest filing, from $4.3 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $8.2 million in Q3 2025 and bottomed at -$6.2 million in Q1 2026.
• The 5-year median for Change in Account Payables is $1.6 million (2024), against an average of $1.3 million.
• Across the five-year window, Change in Account Payables plunged 460.19% in 2023 and jumped 682.92% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at -$801281.0 in 2022, then tumbled by 95.53% to -$1.6 million in 2023, then slipped by 9.65% to -$1.7 million in 2024, then jumped by 348.54% to $4.3 million in 2025, then sank by 244.57% to -$6.2 million in 2026.
• Per Business Quant, the three latest MLTX Change in Account Payables figures stand at -$6.2 million (Q1 2026), $4.3 million (Q4 2025), and $8.2 million (Q3 2025).